Publications by authors named "Ronald Yanagihara"

Claim this Profile
A
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).
Athanassios Argiris, Jieling Miao, Mihaela C Cristea, Allen M Chen, Jacob M Sands, Ronald H Yanagihara

Clin Lung Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
,
, A Novel In-Frame Fusion With Response to Alectinib.
Misako Nagasaka, Nagaratna Sarvadevabatla, Shawn Iwata, Yubin Ge, Ammar Sukari, Ronald Yanagihara

JTO Clin Res Rep· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials.
Nashat Gabrail, Ronald Yanagihara, Marek Spaczyński, William Cooper, Erin O'Boyle

Cancer Manag Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.
Russell K Portenoy, Elena Doina Ganae-Motan, Silvia Allende, Ronald Yanagihara, Lauren Shaiova

J Pain· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Alexander I Spira, Nicholas O Iannotti, Michael A Savin, Marcus Neubauer, Nashat Y Gabrail, Ronald H Yanagihara

Clin Lung Cancer· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
M Catherine Pietanza, Thomas James Lynch, Primo N Lara, John Cho, Ronald H Yanagihara

J Thorac Oncol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
Heinz-Joseph Lenz, Fa-Chyi Lee, Daniel G Haller, Deepti Singh, Al B Benson, Ronald Yanagihara

Cancer· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
Jaffer A Ajani, Fa-Chyi Lee, Deepti A Singh, Daniel G Haller, Heinz-Josef Lenz, Ronald Yanagihara

J Clin Oncol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
Charles L Vogel, Ronald H Yanagihara, Albert J Wood, Frederick M Schnell, Charles Henderson

Oncologist· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Lee S Rosen, David Gordon, N Simon Tchekmedyian, Ronald Yanagihara, Vera Hirsh

Cancer· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Lee S Rosen, David Gordon, Simon Tchekmedyian, Ronald Yanagihara, Vera Hirsh

J Clin Oncol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis